Protect Biotech
15F, No. 508, Sec. 7, Zhongxiao E. Rd., Taipei City, Nangang Dist., 115011, Taiwan
Overview
committed to the research and development of companion animal immunotherapy drugs
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 0
Investment portfolio
- DotBio
Participated · Series A · Aug 2023
DotBio is a Singapore-based biopharmaceutical company developing multi-functional and intracellular antibody therapies for immuno-oncology using its proprietary DotBody platform. The company combines its modular DotBody technology with CoFi and Hot-CoFi stabilization technologies, high-throughput miniaturized assays and data analytics to rapidly prototype multi-functional antibodies. Its platform is designed to generate therapeutic molecules that target both extracellular and intracellular disease drivers and to screen thousands of multi-functional antibody prototypes. DotBio is led by CEO Ignacio Asial. The company recently closed a USD 5.6M Pre-Series A financing to support its near-term plans. It intends to use the funds to commence pre-clinical studies (including animal efficacy and CMC studies) and to scale its DotBody platform ahead of future clinical development.
Team
No current team members are available.